In this field, there are recent data on the beneficial effect of Hsp90 inhibitors in reversing cisplatin resistance of human ovarian cancer cell line (SKOV3), which was mediated by modifying the expression of multidrug-resistance-related genes, especially GSTP1, p53, Bcl-2, survivin, BRCA1, and BRCA2 [54,55]. The gene discussed is GSTP1; the disease is ovarian carcinoma.